Protective effects of irbesartan on apoptosis in experimental diabetic nephropathy
Journal Name:
- Cerrahpaşa Tıp Dergisi
Keywords (Original Language):
Author Name | University of Author | Faculty of Author |
---|---|---|
Abstract (2. Language):
Objectives: The aim of this study is to investigate effects of irbesartan as an Ang II type 1 blocker on apoptosis and anti-apoptotic protein
Bcl-2 in the streptozotocin (STZ)-induced diabetic rat.
Methods: 24 male Wistar albino rats were used for three groups. The first group was the non-diabetic control group. Second group was the
untreated STZ-induced diabetic group, (60 mg/kg, single dose, i.p). The third group was irbesartan treated (15 mg/kg/day, intragastric, for 4
week) STZ-diabetic rats. During the period of the experiment, blood glucose and microalbuminuria levels of the rats were measured. At the
end of the study renal tissue samples were fixed in neutral formalin and embedded in paraffin. Tissue sections were examined for apoptosis
by TUNEL method and for anti-apoptotic protein Bcl-2 by immunohistochemical staining.
Results: The microalbuminuria levels of the irbesartan treated diabetic group were found reduced when compared with the untreated diabetic
group (p<0,001). Widespread apoptosis was seen in the tubules of untreated diabetic group (p<0,01) and a decrease in the immunoreactivity
of Bcl-2 were observed in glomeruli of the diabetic group. In the irbesartan treated diabetic group, antiapoptotic Bcl-2 immunoreactivity
was similar to the results obtained from the control group and a decrease the number of apoptotic cells were observed.
Conclusion: The results suggested that irbesartan treatment has renoprotective effects in STZ-diabetic nephropathy. AT1 receptor blockade
inhibites Ang II mediated apoptosis in the STZ-diabetic nephropathy.
Bookmark/Search this post with
Abstract (Original Language):
Amaç: Bu çalışmada, Angiotensin II tip 1 reseptör blokeri olan irbesartan’ın Streptozotocin (STZ)-diyabetik sıçanlarda apoptoz ve apoptozu
düzenleyen antiapoptotik (Bcl-2) proteini üzerine etkileri araştırıldı.
Yöntem: Çalışmada 24 adet erkek Wistar tipi albino sıçandan oluşan 3 grup kullanıldı. 1.grup; sağlıklı kontrol, 2.grup; tedavisiz STZ-diyabetik
(60 mg/kg, tek doz, i.p), 3.grup; irbesartan (15 mg/kg/gün, intragastrik, 4 hafta) uygulanan STZ-diyabetik sıçan grubu olarak düzenlendi.
Deney süresince tüm gruplardaki sıçanların kan glukoz ve mikroalbuminüri düzeyleri ölçüldü. Deney sonunda alınan böbrek dokuları
nötral formalde tespit edilip parafine gömüldü. Böbrek doku kesitlerine apoptoz tespiti amacıyla TUNEL metodu uygulandı. Bcl-2 antikoru
kullanılarak immunohistokimyasal boyama yapıldı.
Bulgular: İrbesartan uygulanan diyabetik grupta mikroalbuminüri düzeyleri tedavisiz diyabetik grupa kıyasla anlamlı olarak azaldı (p<0,001).
Tedavisiz STZ-diyabetik grupta tubullerde yaygın apoptotik hücreler tespit edilirken (p<0.01), Bcl-2 immun reaktivitesinde azalma gözlendi.
İrbesartan uygulanan diyabetik grupta, diyabetik grup ile kıyaslandığında apoptotik hücrelerin sayısında azalma görülürken, antiapoptotik
Bcl-2 immun reaktivitesinin kontrol gruba yakın olduğu gözlendi.
Sonuç: STZ-diyabeti ile oluşturulan nefropatide, AT1 reseptör blokeri irbesartan uygulamasının renoprotektif etkiye neden olduğu, Ang II
aracılı apoptoz artışını engelleyebileceği sonucuna varıldı.
FULL TEXT (PDF):
- 2
15-22